<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889798</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-TLN</org_study_id>
    <nct_id>NCT00889798</nct_id>
  </id_info>
  <brief_title>Tumor Registry of Lymphatic Neoplasia</brief_title>
  <acronym>TLN-Registry</acronym>
  <official_title>Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to record information on therapy reality of malignant
      lymphatic systemic diseases by office-based haematologists in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record
      information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry
      will follow patients for up to five years. It will identify common therapeutic sequences and
      changes in the treatment of the disease. At inclusion, data in patient characteristics,
      comorbidities, tumor characteristics and previous treatments are collected. During the course
      of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are
      documented.

      The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant
      disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as
      well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in
      patients with multiple myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Course of treatment (treatment reality)</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Documentation of anamnestic data and therapy sequences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of treatment</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions</description>
  </secondary_outcome>
  <enrollment type="Actual">3795</enrollment>
  <condition>Non-Hodgkin's Lymphoma (NHL)</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Multiple Myeloma (MM)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with a malignant lymphatic disease requiring therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Non-Hodgkin`s lymphoma, chronic lymphocytic leukaemia or
             multiple myeloma

          -  Must receive a first- or second-line therapy

          -  18 years or older

          -  Signed, written informed consent

        Exclusion Criteria:

        - no systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Knauf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Haematology, Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfang Abenhardt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MVZ Onkologie im Elisenhof, München, Germany</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <results_reference>
    <citation>Knauf W, Abenhardt W, Dörfel S, Meyer D, Grugel R, Münz M, Hartmann H, Marschner N. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2015 Mar;33(1):15-22. doi: 10.1002/hon.2139. Epub 2014 Apr 15.</citation>
    <PMID>24733536</PMID>
  </results_reference>
  <results_reference>
    <citation>Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, Hartmann H, Marschner N; TLN Study Group. Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncol Res Treat. 2014;37(11):635-6, 638-44. doi: 10.1159/000368315. Epub 2014 Oct 17.</citation>
    <PMID>25486127</PMID>
  </results_reference>
  <results_reference>
    <citation>Knauf W, Aldaoud A, Hutzschenreuter U, Klausmann M, Dille S, Wetzel N, Jänicke M, Marschner N; and the TLN-Group (Tumour Registry Lymphatic Neoplasms). Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms. Ann Hematol. 2018 Dec;97(12):2437-2445. doi: 10.1007/s00277-018-3449-8. Epub 2018 Aug 1.</citation>
    <PMID>30069704</PMID>
  </results_reference>
  <results_reference>
    <citation>Knauf W, Abenhardt W, Mohm J, Rauh J, Harde J, Kaiser-Osterhues A, Jänicke M, Marschner N; TLN-Group (Tumour Registry Lymphatic Neoplasms). Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms. Eur J Haematol. 2019 Nov;103(5):460-471. doi: 10.1111/ejh.13295. Epub 2019 Sep 4.</citation>
    <PMID>31314918</PMID>
  </results_reference>
  <results_reference>
    <citation>Knauf W, Abenhardt W, Slawik HR, Bückner U, Otremba B, Sauer A, Zahn MO, Wetzel N, Kaiser-Osterhues A, Houet L, Marschner N; TLN-Group (Tumour Registry Lymphatic Neoplasms). Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2020 May 8. doi: 10.1002/hon.2740. [Epub ahead of print]</citation>
    <PMID>32383192</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant lymphatic disease</keyword>
  <keyword>therapy-reality</keyword>
  <keyword>observation</keyword>
  <keyword>registry</keyword>
  <keyword>therapy sequences</keyword>
  <keyword>NHL</keyword>
  <keyword>CLL</keyword>
  <keyword>Germany</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>alemtuzumab</keyword>
  <keyword>rituximab</keyword>
  <keyword>bendamustin</keyword>
  <keyword>thalidomide</keyword>
  <keyword>bortezomib</keyword>
  <keyword>ibritumomab-tiuxetan</keyword>
  <keyword>G-CSF (Granulocyte-Colony Stimulating Factor)</keyword>
  <keyword>chronic lymphocytic leukaemia</keyword>
  <keyword>follicular lymphoma</keyword>
  <keyword>gastric MALT lymphoma (Mucosa Associated Lymphoid Tissue)</keyword>
  <keyword>nongastric MALT lymphoma (Mucosa Associated Lymphoid Tissue)</keyword>
  <keyword>nodal marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>diffuse large b-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

